Data cutoff: November 6, 2026, 7:45 p.m. ET. Latest completed U.S. stock trading session: Friday, November 6, 2026; earnings released before the open.
A profitable quarter changes the near-term debate
Moderna's November 6 earnings report offered investors evidence that its respiratory-vaccine business can still generate meaningful revenue while the company invests in a broader mRNA medicines pipeline. For the third quarter of 2026, Moderna reported approximately $1.3 billion in revenue, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss in the comparable 2025 quarter. It also raised its expected full-year revenue growth range to 15%–25%. Those figures were significant because the market has been trying to decide whether Moderna should be valued mainly as a seasonal vaccine producer or as a developer of potentially important oncology treatments. The financial rebound helps fund clinical development, but it does not settle whether experimental cancer programs will obtain approval or generate commercial returns.
What the company reported on November 6
Moderna released results before the regular U.S. trading session and scheduled its conference call for 8:00 a.m. ET. Third-quarter revenue included $780 million from the United States and $533 million from international markets, with stronger overseas COVID-vaccine sales a major driver. GAAP diluted earnings per share were $0.38, compared with a loss of $0.51 a year earlier. Cost of sales was $318 million, including $65 million of third-party royalties. Research and development expense fell 27% to $583 million, reflecting study completions and efficiency measures. Selling, general and administrative costs increased 5% to $282 million. Those components show that profitability improved through a combination of stronger seasonal revenue and lower research spending, rather than through an entirely new product category already generating large sales.
Guidance improved, but the cash number needs context
Management expects 2026 revenue growth of 15%–25%, compared with its previous expectation of growth of up to 10%. It lowered its research-and-development expense forecast to about $2.7 billion from $2.9 billion and expects capital expenditure of around $200 million. Expected year-end cash and investments rose to $8.1 billion–$8.3 billion from $4.7 billion–$5.2 billion. The larger cash estimate must not be attributed entirely to stronger vaccine profits. As the company disclosed, the September-quarter cash position benefited materially from $2.6 billion in net proceeds from convertible notes and related transactions, while a $950 million settlement payment and working-capital needs were offsets. Debt financing can strengthen liquidity without improving the business's underlying operating cash-generation rate.
The approved flu vaccine is not the same as an oncology approval
Moderna reported that the U.S. Food and Drug Administration approved its seasonal influenza vaccine, mFLUSIVA, in August 2026 for adults aged 50–64 and granted accelerated approval for adults aged 65 and older. The company described a limited U.S. launch for the 2026–2027 influenza season because the approval arrived after the usual contracting cycle. This is an important commercial milestone, but it is separate from the status of intismeran autogene, its individualized melanoma therapy developed with Merck. The latter remains an investigational oncology product despite encouraging late-stage results. Investors should never equate approval of one mRNA vaccine with approval of an unrelated cancer program or assume that the same launch economics apply to both.
What the melanoma results suggest—and what they cannot prove
Moderna and Merck previously reported positive Phase 3 data for intismeran combined with Keytruda in certain patients with melanoma. Public coverage described a 42% reduction in the measured risk of recurrence or death in the relevant comparison. That is a relative risk reduction in a defined study population and follow-up period, not a claim that 42% of all cancer patients are cured. Regulatory review, detailed safety data, durability of benefit, manufacturing logistics and reimbursement will determine whether promising trial evidence becomes a viable commercial product. Moderna has discussed a U.S. submission in 2026 and potential commercialization in 2027, but a targeted filing or launch is not an FDA decision. Approval must not be described as completed before the regulator acts.
Market impact and the debate over valuation
Moderna shares gained during Friday's trading session after the revenue surprise and raised outlook, although different reports captured different intraday price moves. The reaction also reflected investor interest in its oncology pipeline and improving liquidity. An upbeat earnings day does not establish what probability of clinical success is already embedded in the share price. Optimists see a stronger balance sheet and a credible path beyond COVID vaccination, including a personalized immunotherapy platform. Skeptics note that COVID products still generate most current revenue, seasonal sales are unpredictable and advanced clinical programs can fail even after promising early or interim data. A company's probability-weighted future revenue is not the same as its optimistic peak-sales scenario.
Key risks in both commercial and scientific execution
COVID vaccine demand depends on public-health recommendations, seasonal uptake, procurement agreements, competition and public attitudes toward vaccination. Newer respiratory vaccines face the challenge of winning orders in crowded markets. In oncology, individualized manufacturing could create complexity around turnaround times, costs and patient access. Trials in additional tumor types cannot borrow efficacy assumptions directly from melanoma. Moderna also faces legal, intellectual-property and financing risks. Management noted a significant prior litigation settlement, and its improved cash outlook partly relied on convertible financing. Lower R&D expenditure may extend financial runway, but investors should ask whether savings reflect sustainable efficiency or fewer promising development opportunities.
The dated next catalyst: November 12 analyst day
Moderna's investor calendar lists an analyst day for Thursday, November 12, 2026, at 9:00 a.m. ET. That is a confirmed opportunity for management to explain clinical priorities, commercial expectations and capital allocation. It is not a scheduled FDA approval date, and no regulatory decision should be assumed merely because the company is holding an investor event. Management has indicated that additional oncology readouts and regulatory milestones are expected, but exact dates were not established for every program in the materials reviewed. Follow official trial disclosures, subsequent regulatory filings and updated cash balances rather than relying on market rumors about imminent approval.
What to watch next and conclusion
The strongest evidence of a durable turnaround would combine repeatable vaccine revenue, improving operating cash flow, successful launch economics for mFLUSIVA and regulatory progress on the oncology portfolio. Watch how much of future revenue depends on seasonal government orders versus broader recurring commercial demand. Compare quarterly cash balances with debt issuance and working-capital changes, not just GAAP net income. Above all, distinguish validated melanoma trial endpoints from still-unproven commercial uptake and expansion into other cancers. Moderna has demonstrated that its existing business can return to quarterly profitability while pursuing a more diversified future. The next investment judgment is how much of that future is supported by completed evidence, and how much remains dependent on clinical, regulatory and execution outcomes.